

## COMPANY ANNOUNCEMENT

### BOARD CHANGES

**Sydney, Australia 24 February 2021** – the Board of Azure Health Technology (AZT) advises that Mr Andrew Bristow has resigned as a Director of the Company, and as a member of the Audit Committee and the Remuneration Committee.

The Board wishes to thank Mr Bristow for his contribution to the Company as a Director and as a member of various committees.

The Board also wishes to advise that Mr Steven Yu is now a non-executive Director.

Dr Glenn Tong  
CEO and Managing Director  
Tel: +61 (0) 412 193 350

Ms Catriona Glover  
Company Secretary  
Tel: +61 (0) 402 328 200

---

#### **About Azure Health Technology Limited**

Azure Health Technology Limited (AZT) is an Australian public unlisted biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. AZT owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines. For more information see: [www.azureht.com.au](http://www.azureht.com.au)

---